News - Otsuka, Research

Filter

Current filters:

OtsukaResearch

Popular Filters

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

09-04-2014

US biotech firm Alkermes saw its shares spike on Tuesday, after it announced positive top-line results…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyLundbeckNeurologicalOtsukaRegulationResearch

Abilify Maintena cuts hospitalization rates for patients with schizophrenia vs oral antipsychotics

07-04-2014

Danish CNS drug specialist Lundbeck and partner Japanese drugmaker Otsuka Pharmaceutical today announced…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck and Otsuka’s brexpiprazole shows efficacy in Phase III trial

Lundbeck and Otsuka’s brexpiprazole shows efficacy in Phase III trial

24-01-2014

Danish CNS drug specialist Lundbeck (LUND: CO) and Japanese drug maker Otsuka (TYO: 4768) have revealed…

brexpiprazoleDenmarkLundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

11-12-2013

Danish CNS specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical say they will further expand…

LicensingLu AF20513LundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck and Otsuka progress new add-on treatment for Alzheimer's

Lundbeck and Otsuka progress new add-on treatment for Alzheimer's

10-10-2013

Denmark-based CNS specialist Lundbeck and partner Japan’s Otsuka Pharmaceutical have announced the…

Lu AE58054LundbeckNeurologicalOtsukaPharmaceuticalResearch

Promising results with Lu AE58054 as add-on to donepezil, in cognitive symptoms of Alzheimer's disease

17-07-2013

Danish CNS specialist Lundbeck (LUN: CO) and Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) presented…

donepezilLu AE58054LundbeckNeurologicalOtsukaPharmaceuticalResearch

Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European

10-07-2013

Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza…

Asia-PacificdelamanidEuropeKyowa Hakko KirinMarkets & MarketingOnglyzaOtsukaPharmaceuticalResearch

Positive trial results for Otsuka and Lundbeck's Abilify Maintena in schizophrenia

22-05-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578)) and Denmark's Lundbeck (LUND: DC) today (May 22)…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

ASN meeting highlights Otsuka's tolvaptan' Alexion's Solaris and Roche's aleglitazar research

05-11-2012

Japan's Otsuka Pharmaceutical (TYO: 4768) that the clinical trial results for tolvaptan, an investigational…

aleglitazarAlexion PharmaceuticalsNephrology and HepatologyOtsukaPharmaceuticalResearchRocheSolaristolvaptan

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko

03-07-2012

Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Positive Ph IIb results for Otsuka TB drug candidate delamanid

07-06-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) has announced Phase IIb clinical trial results on…

Antibiotics and Infectious diseasesdelamanidOtsukaPharmaceuticalResearchRespiratory and Pulmonary

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top